Pharmafile Logo

The science is shifting in oncology: Are you ready to evolve with it?

August 19, 2025 | Inizio, oncology 

- PMLiVE

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke.

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic breast cancer introduced a ground-breaking endpoint – patients progression-free at four years – challenging long-held assumptions.

Key themes included the rise of CAR-T therapies in solid tumors, the dominance of ADCs, and the expanding role of biomarkers in driving precision medicine. Emerging tools like AI-powered biomarker detection and ctDNA for real-time monitoring are reshaping how sequencing, resistance, and adaptive treatments are approached.

Beyond the science, ASCO® 2025 underscored a new strategic imperative: it’s no longer enough to track progress – we must rethink how we plan, communicate, and act on these advances.

Read Patty’s full article here. Watch Inizio’s webinar recap Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025 on demand for the full breakdown.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.

Case study: How segmentation of treaters guided a novel product launch in the allergy space

Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment...

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.